Wednesday Apr 16
Herea s how the government pushes companies to treat kids and rare diseases
BioMarin Pharmaceutical in Novato and San Rafael has six more months to keep exclusively selling a new, kid-friendly form of its drug for a disease called phenylketonuria.
Trending on the Topix Network
Tue Apr 15, 2014
Zacks Reiterates "Neutral" Rating for BioMarin Pharmaceutical
's stock had its "neutral" rating reaffirmed by Zacks in a note issued to investors on Tuesday, American Banking News.com reports.
Analysts View on Biotech Equities -- Research on Organovo Holdings,...
The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, while the same has fallen by 1.86% in the previous three months.
Mon Apr 14, 2014
FDA Extends Market Exclusivity of KUVAN Powder for Oral Solution and Tablets
BioMarin Pharmaceutical today announced that the FDA granted KUVAN Powder for Oral Solution and Tablets a six-month pediatric exclusivity extension.
Fri Apr 11, 2014
Clinical Trial Results and Initiation, Endowment, Product Launches,...
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. , Questcor Pharmaceuticals, Inc. , Jazz Pharmaceuticals plc , Ariad Pharmaceuticals, Inc. , and BioMarin Pharmaceutical Inc. .
Thu Apr 10, 2014
Marin Independent Journal
San Rafael conceptually approves six-story parking garage for BioMarin
San Rafael's Design Review Board has conceptually approved a plan by BioMarin Pharmaceutical to build a six-story parking garage across from the San Rafael Corporate Center bordered by Second Street and Lincoln Avenue.
Mon Apr 07, 2014
The Motley Fool
The AACR Annual Meeting May Move These 2 Stocks
The American Association for Cancer Research meeting shines a bright light on gene testing like that performed by Myriad, and on promising late stage breast cancer treatments, including Pfizer's palbociclib.
Tue Apr 01, 2014
Clinovo Release: Silicon Valley BioTalks - Manage Outsourced And In House Clinical Trials
March 31, 2014 -- Outsourcing experts from Onyx Pharmaceuticals, San Francisco State University , BioMarin Pharmaceutical, and Clinovo discussed the topic 'Manage In-house and Outsourced Clinical Trials: Vendor Selection, Project Coordination, and Resource Management' at the eighth Silicon Valley BioTalks.
Mon Mar 31, 2014
The Business Journal
Ultragenyx plans to double Marin staff
Coming off a recent $139 million initial public offering of stock, Ultragenyx Pharmaceutical, Inc., is doubling the size of its headquarters as it enters latter stages of research and development of some of its treatments for rare diseases.
Tue Mar 25, 2014
Stock Downgrades: JPMorgan Drives the Corner Store Round the Bend
Blame Moscow if you must, but the root cause of the market's stumbles on Monday lay much closer to home.
Mon Mar 24, 2014
Goldman Sachs Downgrades BioMarin Pharmaceutical to Neutral
Shares of BioMarin Pharmaceutical traded down 0.30% during mid-day trading on Monday, hitting $73.71.